Human Genome Sciences (HGSI) CEO Buys 100K Shares
More News related to HGSI
- Human Genome (HGSI) straddles expensive into Phase Three data
- Human Genome Sciences to Host July 20 Conference Call to Discuss Top-Line Phase 3 Results for Benlysta(TM) (Formerly Lymphostat-B(R)) in Systemic Lupus Erythematosus
- Human Genome (HGSI) options expensive into Phase Three data
- Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Piper Jaffray Conference
- Human Genome Sciences Announces Completion of Enrollment in Phase 2b Monthly-Dosing Trial of Albuferon(R)
Human Genome Sciences Inc. (Nasdaq: HGSI)President and CEO, Thomas Watkins, purchased 100,000 shares on 11/12 at a price of $2.02, bringing his stake to 170,274 shares.
Human Genome Sciences, Inc. operates as a biopharmaceutical company in the Unites States.
Related Categories
Insider TradesStocks Mentioned
-0.04Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
